Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Autor: | Michael A, Nauck, David A, D'Alessio |
---|---|
Rok vydání: | 2022 |
Předmět: |
Clinical Trials as Topic
Endocrinology Diabetes and Metabolism Body Weight Gastric Inhibitory Polypeptide Glycemic Control Glucagon-Like Peptide-1 Receptor Diabetes Mellitus Type 2 Meta-Analysis as Topic Cardiovascular Diseases Glucagon-Like Peptide 1 Weight Loss Humans Hypoglycemic Agents Insulin Cardiology and Cardiovascular Medicine |
Zdroj: | Cardiovascular Diabetology. 21 |
ISSN: | 1475-2840 |
Popis: | Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. Five clinical trials in type 2-diabetic subjects (SURPASS 1–5) have shown that tirzepatide at 5–15 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.4–11.7 kg) by amounts unprecedented for a single agent. A sizable proportion of patients (23.0 to 62.4%) reached an HbA1c of 1c and body weight than the selective GLP-1 RA semaglutide (1.0 mg per week), and titrated basal insulin. Adverse events related to tirzepatide were similar to what has been reported for selective GLP-1RA, mainly nausea, vomiting, diarrhoea, and constipation, that were more common at higher doses. Cardiovascular events have been adjudicated across the whole study program, and MACE-4 (nonfatal myocardial infarction, non-fatal stroke, cardiovascular death and hospital admission for angina) events tended to be reduced over up to a 2 year-period, albeit with low numbers of events. For none of the cardiovascular events analysed (MACE-4, or its components) was a hazard ratio > 1.0 vs. pooled comparators found in a meta-analysis covering the whole clinical trial program, and the upper bounds of the confidence intervals for MACE were |
Databáze: | OpenAIRE |
Externí odkaz: |